MiR-328 sensitizes cells to radiotherapy by targeting histone H2AX both in osteosarcoma [241] and lung cancer [242]; furthermore, in lung cancer mir-138 [243] and miR-30a [235] were also found as radiosensitizing agents via H2AX targeting. This evidence concerns the gene H2AX and osteosarcoma.